1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Lebanon Pharmaceuticals and Healthcare Report Q1 2017

Lebanon Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 77 pages

Includes 3 FREE quarterly updates


BMI View:

The ongoing Syrian civil war has had a substantial impact on Lebanon's healthcare service and finances, with a troubled political climate further exacerbating the crisis. On a positive note, the influx of international funds to help with the country's refugee surge has led to an increase in primary healthcare centres opening, providing greater access to the country's most vulnerable people. Over the long term, we expect a growing and ageing population, coupled with relatively high per capita spending, to contribute to rising sales of high-value medicines, keeping Lebanon amongst the most attractive pharmaceutical markets in the Middle East and African region.

Headline Expenditure Projections



- Pharmaceuticals: LBP2.47trn (USD1.64bn) in 2015 to LBP2.60trn (USD1.73bn) in 2016; +5.6% in local currency and US dollar terms. Forecast in line with last quarter.

- Healthcare: LBP5.04trn (USD3.34bn) in 2015 to LBP5.28trn (USD3.50bn) in 2016; +4.8% in local currency and US dollar terms. Forecast in line with last quarter. Risk/Reward Index For Q117, Lebanon's Pharmaceutical Risk/Reward Index (RRI) score is calculated at 52.8 out of 100, unchanged from last quarter's score. The country's score sits between Kuwait (53.3) and South Africa (52.6), making it the fifth most attractive market out of 33 in our Middle East and Africa matrix. Despite increased demand for modern medicines, population growth (score of 4.5 out of 5) and healthcare service improvements, Lebanon's pharmaceutical market is heavily constrained by the relatively small population and limited funding (Market Expenditure score of 8.0 out of 20).

Table Of Contents

Lebanon Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Lebanon 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Lebanon 2012-2020) 13
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Lebanon 2012-2020) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Lebanon 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Lebanon 2012-2020) 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Lebanon 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Lebanon 2012-2020) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Lebanon 2012-2020) 26
OTC Medicine Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Lebanon 2012-2020) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Lebanon 2014-2020) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Lebanon 2014-2020) 32
Industry Risk/Reward Index 33
Middle East And Africa Risk/Reward Index - Q1 2017 33
Lebanon Risk/Reward Index 41
Rewards 41
Risks 41
Regulatory Review 43
Intellectual Property Issues 45
Pricing Regime 47
Reimbursement Regime 49
Market Overview 50
Healthcare Sector 51
Clinical Trials 54
Epidemiology 56
Competitive Landscape 58
Research-Based Industry 58
Table: Multinational Market Activity 59
Generic Drugmakers 59
Pharmaceutical Distribution 60
Pharmaceutical Retail Sector 61
Company Profile 62
Algorithm 62
Pharmaline 64
Demographic Forecast 66
Table: Population Headline Indicators (Lebanon 1990-2025) 67
Table: Key Population Ratios (Lebanon 1990-2025) 67
Table: Urban/Rural Population and Life Expectancy (Lebanon 1990-2025) 68
Table: Population By Age Group (Lebanon 1990-2025) 68
Table: Population By Age Group % (Lebanon 1990-2025) 69
Glossary 71
Methodology 73
Pharmaceutical Expenditure Forecast Model 73
Healthcare Expenditure Forecast Model 73
Notes On Methodology 74
Risk/Reward Index Methodology 75
Index Overview 76
Table: Pharmaceutical Risk/Reward Index Indicators 76
Indicator Weightings 77

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.